
Takeda has decided to discontinue its Phase 3 study of Ninlaro (ixazomib) after the drug in combination with dexamethasone, failed …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

